SAN FRANCISCO and NEW YORK, July 27, 2022 (GLOBE NEWSWIRE) — Siapsi®, a leading real-world evidence company dedicated to ending the fear and burden of serious diseases by advancing real-world care, today announced the closing of a $35 million financing transaction to expand Syapse’s focus on delivering world-class insights real for partners and assistance. those in improving outcomes for people with cancer. The investment is managed by a subsidiary of Innovatus Capital Partners, LLC (Innovatus)with participation from existing investors including Ally Bridge Group, Merck Global Health Innovation Fund, Northpond Ventures, Revelation Alpine LLC, Safeguard Scientifics and Social Capital.
“Innovatus is excited to fund Syapse’s highly scalable, value-added business that is being embedded in leading community health systems and relevant to life science companies based on its ability to deliver real-world evidence (RWE ) and to provide actionable knowledge”, he said. Claes Ekstrom, Managing Director and Head of Life Sciences Strategy at Innovatus.
Syapse has expanded its Learning Health Network by partnering with some of the nation’s leading community health systems to support precision medicine strategies aimed at improving clinical outcomes, reducing costs and improving the experience of their patients. In addition, Syapse has added life sciences partnerships with established biopharmaceutical companies. Syapse recently presented research at the American Society of Clinical Oncology (ASCO) focused on how applying machine learning to real-world data can be used to power precision medicine solutions.
“We are extremely pleased that Innovatus supports our mission to marry technology and real-world data to deliver high-quality healthcare to cancer patients by transforming provider-driven data into actionable insights for health systems and life sciences,” said Ken Tarkoff, chief executive officer. officer of the Syapse.
Armentum Partners acted as financial advisor to Syapse for this transaction.
Syapse is a company dedicated to ending the fear and burden of oncology and other serious diseases by advancing care in the real world. By merging clinical expertise with smart technologies, we transform data into evidence—and then into experience—in collaboration with our network of partners who are committed to improving the lives of patients through community health systems. Together, we connect comprehensive patient insights to our network to empower our partners to drive real impact and improve access to high-quality care.
About Innovatus Capital Partners, LLC
Innovatus Capital Partners, LLC, is an independent advisor and asset management firm with approximately $1.7 billion in assets under management. Innovatus adheres to an investment strategy that identifies disruptive and growth opportunities across multiple asset classes with a unifying theme of capital preservation, income generation and upside options. The firm has a dedicated team of life sciences investment professionals with deep experience in healthcare, including life sciences. Innovatus and its principals have significant experience in providing debt financing to medical device, diagnostics and biotechnology companies that address unmet medical needs, improve patient outcomes and reduce overall healthcare costs. To date, Innovatus Life Sciences Strategy has made over $1.1 billion in capital commitments in debt and equity support. Further information can be found at www.innovatuscp.com.
Source: Syapse Inc.